Bochie that jump in sales is mainly a function of screening sales taking off.
Realisticaly it will take GBI a few years to build up a reasonable set of data (marketing material) for screening sales to become meaningful...that number in 2012 assumes a PapType market share of 10% of screening tests and 50% of Australia & NZ markets.
In screening market 2010 market share assumed is 2% whilst 2011 is 4%.
The ASCUS/triage sales from 2010-2011 are the low hanging fruit so to speak and can get GBI profitable whilst building the data for the larger screening market.
cheers
- Forums
- ASX - By Stock
- gbi valuation - part 2
Bochie that jump in sales is mainly a function of screening...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GBI (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online